Division of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine, Shimotsuke 329-0498, Tochigi, Japan.
Division of Structural Biochemistry, Department of Biochemistry, Jichi Medical University School of Medicine, Shimotsuke 329-0498, Tochigi, Japan.
Viruses. 2024 Aug 31;16(9):1400. doi: 10.3390/v16091400.
The zoonotic transmission of hepatitis E virus (HEV) genotypes 3 (HEV-3) and 4 (HEV-4), and rabbit HEV (HEV-3ra) has been documented. Vaccination against HEV infection depends on the capsid (open reading frame 2, ORF2) protein, which is highly immunogenic and elicits effective virus-neutralizing antibodies. () is utilized as an effective system for producing HEV-like particles (VLPs). However, research on the production of ORF2 proteins from these HEV genotypes in E. coli to form VLPs has been modest. In this study, we constructed 21 recombinant plasmids expressing various N-terminally and C-terminally truncated HEV ORF2 proteins for HEV-3, HEV-3ra, and HEV-4 in . We successfully obtained nine HEV-3, two HEV-3ra, and ten HEV-4 ORF2 proteins, which were primarily localized in inclusion bodies. These proteins were solubilized in 4 M urea, filtered, and subjected to gel filtration. Results revealed that six HEV-3, one HEV-3ra, and two HEV-4 truncated proteins could assemble into VLPs. The purified VLPs displayed molecular weights ranging from 27.1 to 63.4 kDa and demonstrated high purity (74.7-95.3%), as assessed by bioanalyzer, with yields of 13.9-89.6 mg per 100 mL of TB medium. Immunoelectron microscopy confirmed the origin of these VLPs from HEV ORF2. Antigenicity testing indicated that these VLPs possess characteristic HEV antigenicity. Evaluation of immunogenicity in Balb/cAJcl mice revealed robust anti-HEV IgG responses, highlighting the potential of these VLPs as immunogens. These findings suggest that the generated HEV VLPs of different genotypes could serve as valuable tools for HEV research and vaccine development.
已记录到戊型肝炎病毒 (HEV) 基因型 3 (HEV-3) 和 4 (HEV-4) 以及兔 HEV (HEV-3ra) 的人畜共患病传播。针对 HEV 感染的疫苗接种取决于衣壳 (开放阅读框 2,ORF2) 蛋白,该蛋白具有高度免疫原性,并能引发有效的病毒中和抗体。() 被用作生产 HEV 样颗粒 (VLPs) 的有效系统。然而,关于在大肠杆菌中生产这些 HEV 基因型的 ORF2 蛋白以形成 VLPs 的研究进展不大。在这项研究中,我们构建了 21 个重组质粒,用于表达来自 HEV-3、HEV-3ra 和 HEV-4 的各种 N 端和 C 端截断的 HEV ORF2 蛋白。我们成功获得了 9 个 HEV-3、2 个 HEV-3ra 和 10 个 HEV-4 ORF2 蛋白,这些蛋白主要定位于包涵体中。这些蛋白在 4 M 尿素中溶解,过滤并进行凝胶过滤。结果表明,6 个 HEV-3、1 个 HEV-3ra 和 2 个 HEV-4 截断蛋白可以组装成 VLPs。纯化的 VLPs 的分子量范围为 27.1 至 63.4 kDa,生物分析仪评估显示纯度高达 74.7-95.3%,每 100 mL TB 培养基的产量为 13.9-89.6 mg。免疫电子显微镜证实这些 VLPs 来源于 HEV ORF2。抗原性测试表明,这些 VLPs 具有特征性的 HEV 抗原性。在 Balb/cAJcl 小鼠中的免疫原性评估显示出强烈的抗-HEV IgG 反应,突出了这些 VLPs 作为免疫原的潜力。这些发现表明,不同基因型的生成的 HEV VLPs 可以作为 HEV 研究和疫苗开发的有价值的工具。